Olanzapine vs. other antipsychotics in actual out-patient settings: Six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study

Acta Psychiatrica Scandinavica

Volumn 111, Issue 3, 2005, Pages 232-243

  Lambert, Martin ^a,d   Haro, J M ^b   Novick, D ^c   Edgell, E T ^c   Kennedy, L ^c   Ratcliffe, M ^c   Naber, B ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b PARC SANITARI SANT JOAN DE DÉU   (Spain)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Adverse effects; Amisulpridel; Antipsychotic agents; Clozapine; Olanzapine; Quetiapine; Risperidone; Schizophrenia

Indexed keywords

AMISULPRIDE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AMENORRHEA; ANTICHOLINERGIC EFFECT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL OBSERVATION; CLINICAL TRIAL; COHORT ANALYSIS; DOSE TIME EFFECT RELATION; DRUG TOLERABILITY; EUROPE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; OUTPATIENT; PRIORITY JOURNAL; PSYCHOSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; WEIGHT GAIN;

ADULT; AMBULATORY CARE; AMENORRHEA; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; CLOZAPINE; DIBENZOTHIAZEPINES; DRUG TOLERANCE; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMANS; MALE; OBSERVATION; OUTCOME ASSESSMENT (HEALTH CARE); RISPERIDONE; SCHIZOPHRENIA;

EID: 14844297025     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2004.00451.x     Document Type: Article

References (63)

1. CASEY DE. Motor and mental aspects of acute extra-pyramidal syndromes. Acta Psychiatr Scand 1994;89(Suppl. 380):14-20.
2. WHITWORTH AB, FLEISCHHACKER W. Adverse effects of anti-psychotic drugs. Int Clin Psychopharmacol 1995;9 (Suppl. 5):21-27.
3. TANDON R, JIBSON MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 2002;14:123-129.
4. LEUCHT S, PITSCHEL-WALZ G, ABRAHAM D, KISSLING W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine. quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
5. LEUCHT S, PITSCHEL-WALZ G, ENGEL RR, KISSLING W. Amisulpride an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-190.
6. CAROFF SN, MANN SC, CAMPBELL EC, SULLIVAN KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002;63(Suppl. 4):12-19.
7. FRIEDMAN JH. Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocrinology 2003;28(Suppl. 1): 39-51.
8. HELLEWELL JS. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002;16:457-471.
9. ALLISON DB, MACKELL JA, MCDONNELL DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003;54:565-567.
10. LAMBERT M, SCHIMMELMANN B, KAROW A, NABER D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance. Pharmacopsychiatry 2003;36(Suppl 3):181-190.
11. BAPTISTA T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999;100:3-16.
12. GREEN A, PATEL J, GOISMAN R. ALLISON D. BLACKBURN G. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000;22:224-235.
13. SUSSMAN N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62(Suppl. 23):5-12.
14. NASRALLAH H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinol 2003;28:83-96.
15. KAPUR S, LANGLOIS X, VINKEN P, MEGENS AA, DE COSTER R, ANDREWS JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002;302:1129-1134.
16. PEUSKENS J, SIENAERT P, DE HERT M. Sexual dysfunction: the unspoken side-effect of antipsychotics. Eur Psychiatry 1998;13(Suppl. 1):23-30.
17. DAVID SR, TAYLOR CC, KINON BJ, BREIER AL. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22:1085-1096.
18. TURRONE P, KAPUR S, SEEMAN MV, FLINT AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159:133-135.
19. HALBREICH U, KINON BJ, GILMORE JA, KAHN LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinol 2003;28(Suppl. ):53-67.
20. LAMBERT M, CONUS P, LAMBERT T, MCGORRY P. Pharmacotherapy of first episode schizophrenia. Exp Opin Pharmacother 2003;4:717-751.
21. CUTLER AJ. Sexual dysfunctions and antipsychotic treatment. Psychoneuroendocrinol 2003;28:69-82.
22. HARO JM, EDGELL ET, FREWER P, ALONSO J, JONES PB on behalf of the SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand 2003;107(Suppl. 416):7-15.
23. HARO JM, EDGELL ET, JONES PB et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003;107:222-223.
24. GUY W. (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976.
25. HARO JM, KAMATH SA, OCHOA S et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003;416:16-23.
26. PRIETO L, NOVICK D, SACRISTAN JA et al on behalf of the SOHO Study Group. A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatr Scand Suppl 2003;416:24-29.
27. LIANG KY, ZEGER SL. Longitudinal data analysis using generalized linear models. Biometrika 1988;73:13-22.
28. HARO JM, EDGELL E, NOVICK D et al. Effectiveness of antipsychotic treatment for schizophrenia in the outpatient setting. Six-months results of the European SOHO study involving over 10,000 patients. Acta Psychiatrica Scandinavica (in press).
29. SIMPSON GM, ANGUS JWS. A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scand 1970;212:11-19.
30. TOLLEFSON GD, BEASLEY CM Jr, TRAN PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaboration study. Am J Psychiatry 1997;154:457-465.
31. MCGORRY PD, KILLACKEY E, LAMBERT M, ELKINS K, LAMBERT T. Summary Australian and New Zealand Clinical Practice Guidelines for the treatment of schizophrenia. Australasian Psychiatry 2003;11:1-13.
32. CONLEY RR, MAHMOUD R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-774.
33. CURRAN MP, PERRY CM. Spotlight on amisulpride in schizophrenia. CNS Drugs 2002;16:207-211.
34. CUTLER AJ, GOLDSTEIN JM, TUMAS JA. Related dosing and switching strategies for quetiapine fumarate. Clin Ther 2002;24:209-222.
35. SPINA E, AVENOSO A, FACCIOLA G et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 2000;148:83-89.
36. LEUCHT S, WAHLBECK K, HAMANN J, KISSLING W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. The Lancet 2003;361:1581-1589.
37. LAMBERT M. Adverse neuroleptic effects and their treatment. In: NABER D, LAMBERT M, KRAUSZ M, HAASEN C, PICKAR D, eds. Atypical neuroleptics in the treatment of schizophrenic patients, 2nd edn. Bremen, Germany: UNI-MED, 2002:101-130.
38. TARSY D, BALDESSARINI RJ, TARAZI FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45.
39. PERKINS DO. Predictors of non-compliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128.
40. KANE JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001;11(Suppl. 4):S397-403.
41. KAMPMAN O, LEHTINEN K. Compliance in psychoses. Acta Psychiatr Scand 1999;100:167-175.
42. SPOHN HE, STRAUSS ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989;98:367-380.
43. DUKE PJ, PANTELIS C, BARNES TR. South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 1994;164:630-636.
44. CHOUINARD G, ANNABLE L, ROSS-CHOUTNARD A, MERCIER P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8(4 Suppl.):21-26.
45. LEWANDER T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand Suppl 1994;380:8-13.
46. ROBINSON DG, WOERNER MG, ALVIR JM et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549.
47. BOUMANS CE, DE MOOU KJ, KOCH PA, VAN'T HOF MA, ZITMAN FG. Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia? Schizophr Bull 1994; 20:339-344.
48. ARONNE LJ. Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatry 2001;62 (Suppl. 23):13-22.
49. SUSSMAN N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmcol 2003;23(3 Suppl. 1):S21-26.
50. MCINTYRE RS, MANCINI DA, BASILE VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001; 62(Suppl. 23):23-29.
51. ALLISON DB, MENTORE JL, HEO M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696.
52. BOBES J, REJAS J, GARCIA-GARCIA M et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003;62:77-88.
53. BASSON BR, KINON BJ, TAYLOR CC, SZYMANSKI KA, GILMORE JA. TOLLEFSON GD: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry 2001;62:231-238.
54. KINON BJ, BASSON BR, GILMORE JA, TOLLEFSON GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100.
55. BASILE VS, MASELLIS M, MCINTYRE RS, MELTZER HY, LIEBERMAN JA, KENNEDY JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62(Suppl. 23):45-66.
56. CZOBOR P, VOLAVKA J, SHEITMAN B et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22:244-251.
57. MACDONALD S, HALLIDAY J, MACEWAN T et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction: case-control study. Br J Psychiatry 2003;182:50-56.
58. TRAN PV, HAMILTON SH, KUNTZ AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmcol 1997;17:407-418.
59. BOBES J, GARC A-PORTILLA MP, REIAS J et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29:125-147.
60. WIECH A, HADDAD PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199-204.
61. GOODNICK PJ, RODRIGUEZ L, SANTANA O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002;3:1381-1391.
62. JUUL POVLSEN U, NORING U, FOG R, GERLACH J. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985;71:176-185.
63. IQBAL MM, RAHMAN A, HUSAIN Z, MAHMUD SZ, RYAN WG, FELDMAN JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003;15:33-48.